Kinnate Biopharma

$19.51 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Kinnate Biopharma

Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Company utilizes its deep specialization in structure-based drug discovery, translational research and patient-driven precision medicine, which is collectively referred as Kinnate Discovery Engine, to develop its targeted therapies. The Company's advanced product candidate is KIN-2787, which is a rapidly accelerated fibrosarcoma (RAF) inhibitor, which is being developed for the treatment of patients with lung cancer, melanoma and other solid tumors. The Company's other product candidate include KIN-3248 and KIN004.

Stock Analysis

last close $19.77
1-mo return -20.9%
3-mo return -16.5%
avg daily vol. 108.73T
52-week high 48.75
52-week low 17.58
market cap. $835M
forward pe -
annual div. -
roe -51.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 90.2%
baraka

Subscribe now for daily local and international financial news

Subscribe